Literature DB >> 8820422

Effect of probenecid on the distribution, metabolism, and excretion of cidofovir in rabbits.

K C Cundy1, Z H Li, W A Lee.   

Abstract

The effect of concomitant probenecid on the tissue distribution, metabolism, and urinary excretion of cidofovir was examined in New Zealand white rabbits. Two groups of six male rabbits received intravenous [3H]cidofovir (5 mg/kg, 20 mu Ci/kg) alone or with concomitant intravenous probenecid (90 mg/kg). Radioactivity in kidney at 15 min postdose was decreased 70% by probenecid; plasma levels at 15 min postdose were increased 65% by probenecid. These effects were diminished at later time points. The estimated elimination half-life of cidofovir from the kidney was 16 hr in the presence of probenecid and 11 hr without probenecid. Two additional groups of six rabbits received intravenous [14C]cidofovir (15 mg/kg, 100 mu Ci/kg) alone or 1 hr after oral administration of probenecid (90 mg/kg). Radioactivity was highest in the kidney (approximately 700 mu g-eq/g at 30 min postdose). Probenecid did not affect the gross distribution of radioactivity. However, autoradiography of left kidneys revealed localization of the drug in the renal cortex; radioactivity in the cortex at 30 min postdose was decreased 50% by probenecid. These data are consistent with inhibition of tubular secretion of cidofovir by probenecid. More than 73% of the cidofovir dose was recovered in the urine in 24 hr. Urine contained unchanged cidofovir (>97%) and a metabolite coeluting with authentic cidofovir phosphocholine (2%). This metabolite also accounted for approximately 1-4% of the radioactivity in rabbit kidney.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8820422

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  9 in total

Review 1.  The role of transporters in the toxicity of nucleoside and nucleotide analogs.

Authors:  Christopher A Koczor; Rebecca A Torres; William Lewis
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-04-18       Impact factor: 4.481

2.  Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis.

Authors:  J Ambati; K B Wynne; M C Angerame; M R Robinson
Journal:  Br J Ophthalmol       Date:  1999-10       Impact factor: 4.638

3.  Pharmacokinetics of low-dose cidofovir in kidney transplant recipients with BK virus infection.

Authors:  J D Momper; Y Zhao; R Shapiro; K S Schonder; Y Gao; P S Randhawa; R Venkataramanan
Journal:  Transpl Infect Dis       Date:  2012-10-02       Impact factor: 2.228

Review 4.  Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir.

Authors:  K C Cundy
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

Review 5.  Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant.

Authors:  Susan M Abdel-Rahman; Jason G Newland; Gregory L Kearns
Journal:  Paediatr Drugs       Date:  2011-02-01       Impact factor: 3.022

Review 6.  Toward a systems level understanding of organic anion and other multispecific drug transporters: a remote sensing and signaling hypothesis.

Authors:  Sun-Young Ahn; Sanjay K Nigam
Journal:  Mol Pharmacol       Date:  2009-06-10       Impact factor: 4.436

7.  Clinical pharmacokinetics of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine in human immunodeficiency virus-infected patients.

Authors:  K C Cundy; P Barditch-Crovo; B G Petty; A Ruby; M Redpath; H S Jaffe; P S Lietman
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

8.  Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation.

Authors:  Tomas Cihlar; Genevieve Laflamme; Robyn Fisher; Anne C Carey; Jennifer E Vela; Richard Mackman; Adrian S Ray
Journal:  Antimicrob Agents Chemother       Date:  2008-11-10       Impact factor: 5.191

9.  Brincidofovir Is Not a Substrate for the Human Organic Anion Transporter 1: A Mechanistic Explanation for the Lack of Nephrotoxicity Observed in Clinical Studies.

Authors:  Timothy K Tippin; Marion E Morrison; Thomas M Brundage; Hervé Momméja-Marin
Journal:  Ther Drug Monit       Date:  2016-12       Impact factor: 3.681

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.